Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support

Clinical Cancer Research

Volumn 4, Issue 6, 1998, Pages 1443-1449

  Elias, Anthony D ^a,f   Wheeler, Catherine ^d   Ayash, Lois J ^a   Schwartz, Gary ^a   Ibrahim, Joseph ^b   Mills, Letha ^e   McCauley, Mary ^a   Coleman, Norman ^c   Warren, Diane ^a   Schnipper, Lowell ^d   Antman, Karen H ^a   Teicher, Beverly A ^a   Frei III, Emil ^a  

^a Laboratory of Gynecologic Oncology   (United States)

^b Division of Biostatistics   (United States)

^c HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETANIDAZOLE; ETOPOSIDE; IFOSFAMIDE;

ARTICLE; CROSS LINKING; DNA DAMAGE; DNA REPAIR; DOSE CALCULATION; DRUG MEGADOSE; HEART ARREST; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HYPOXIC CELL; PRIORITY JOURNAL; RADIOSENSITIZATION; STEM CELL; STEM CELL TRANSPLANTATION; TREATMENT FAILURE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CELL HYPOXIA; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ETANIDAZOLE; ETOPOSIDE; EXPECTORANTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; MALE; MESNA; MIDDLE AGED; NEOPLASMS; RECURRENCE; SURVIVAL RATE;

EID: 0031801392     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Gatenby, R. A., Kessler, H. B., Rosenblum, J. S., Coia, L. R., Moldofsky, P. J., Hartz, W. H., and Broder, G. J. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 14: 831, 1988.
2. Kennedy, K. A., Teicher, B. A., Rockwell, S., and Sartorelli, A. C. The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem. Pharmacol., 21: 1-8, 1980.
3. Midander, J., Deschanvanne, P., Malaise, E., and Revesz, L. Survival curves of irradiated glutathione-deficient human fibroblasts: indication of a reduced enhancement of radiosensitivity by oxygen and misonidazole. Int. J. Radiat. Oncol. Biol. Phys., 8: 443-446, 1982.
4. Teicher, B. A., Lazo, J. S., and Sartorelli, A. C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res., 41: 73-81, 1981.
5. Coleman, C. N., Bump, E. A., and Kramer, R. A. Chemical modifiers of cancer treatment. J. Clin. Oncol., 6: 709-733, 1988.
6. Siemann, D. W., and Mulcahy, R. T. Sensitization of cancer chemotherapeutic agents by nitroheterocyclics. Biochem. Pharmacol., 35: 111-115, 1986.
7. Mulcahy, R. T. Cross-link formation and chemopotentiation of EMT-6/Ro cells exposed to MISO after CCNU treatment in vitro. Int. J. Radiat. Oncol. Biol. Phys., 12: 1389-1392, 1986.
8. Murray, D., and Meyn, R. E. Enhancement of DNA cross-linking activity of melphalan by misonidazole in vivo. Br. J. Cancer, 47: 195-203, 1983.
9. Ramonas, L. M., Erickson, L. C., and McManus, M. E. The effect of misonidazole on the cytotoxicity and DNA cross-linking activity of an activated sulfidocyclophosphamide in hypoxic mouse leukemia cells. Mol. Pharmacol., 22: 175-181, 1982.
10. Taylor, Y. C., Evans, J. W., and Brown, J. M. Mechanism of sensitization of Chinese hamster ovary cells to melphalan by hypoxic treatment with misonidazole. Cancer Res., 43: 3175-3181, 1983.
11. Varnes, M. E., Biaglow, J. E., and Koch, C. J. In: L. W. Brady (ed.). Radiation Sensitizers: Their Use in the Clinical Management of Cancer, p. 121. New York: Masson, 1980.
12. Lee, F. Y. F., and Workman, P. Misonidazole and CCNU: further evidence for a pharmacokinetic mechanism of chemosensitization and therapeutic gain. Br. J. Cancer, 49: 579-595, 1984.
13. Lee, F. Y. F., Workman, P., and Cheeseman, K. H. Misonidazole and benznidazole inhibit hydroxylation of CCNU by mouse liver microsomal cytochrome P-450 in vitro. Biochem. Pharmacol., 36: 1349-1355, 1987.
14. Teicher, B. A., Holden, S. A., Al-Achi, A., and Herman, T. S. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res., 50: 3339-3344, 1990.
15. Teicher, B. A., Herman, T. S., Shulman, L., Bubley, G., Coleman, C. N., and Frei, E., III. Combination of etanidazole with cyclophosphamide and platinum complexes. Cancer. Chemother. Pharmacol., 28: 153-158, 1991.
16. Teicher, B. A., Herman, T. S., Tanaka, J., Eder, J. P., Holden, S. A., Bubley, G., Coleman, C. N., and Frei, E., III. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma. Cancer Res., 51: 1086-1091, 1991.
17. Teicher, B. A., Bernal, S. D., Holden, S. A., and Cathcart, K. N. S. Additive effect of Fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity. Cancer Chemother. Pharmacol., 21: 281-285, 1988.
18. Teicher, B. A., Herman, T. S., Holden, S. A., and Jones, S. M. Addition of misonidazole, etanidazole or hyperthermia to treatment with Fluosol-DA/carbogen/radiation. J. Natl. Cancer Inst. (Bethesda), 81: 929-934, 1989.
19. Teicher, B. A., Holden, S. A., and Rose, C. M. Effect of oxygen on the cytotoxicity and antitumor activity of etoposide. J. Natl. Cancer Inst. (Bethesda), 75: 1129-1133, 1985.
20. Elias, A., Ayash, L., Wheeler, C., Schwartz, G., McCauley, M., Teicher, B. A., Coleman, N., Eickhoff, C., Warren, D., Schnipper, L., Antman, K., and Frei, E., III. Phase I dose escalation of the hypoxic cell sensitizer etanidazole (ETA) combined with high dose ifosfamide, carboplatin and etoposide (ICE) and autologous stem cell support. Proc. Am. Soc. Clin. Oncol., 14: 180, 1995.
21. Elias, A. D., Ayash, L., Wheeler, C., Schwartz, G., Tepler, I., Gonin, R., McCauley, M., Mazanet, R., Schnipper, L., Frei, E., and Antman, K. H. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant., 15: 373-379, 1995.
22. Slevin, M. L., Clark, P. I., Joel, S. P., Malik, S., Osborne, R. J., Gregory, W. M., Lowe, D. G., Reznek, R. H., and Wrigley, P. F. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J. Clin. Oncol., 7: 1333-1340, 1989.
23. Creagan, E. T., Richardson, R. L., and Kovach, J. S. Pilot study of a continuous five-day i.v. infusion of etoposide concomitant with cisplatin in selected patients with advanced cancer. J. Clin. Oncol., 6: 1197-1201, 1988.
24. Elias, A. D., Ayash, L., Eder, J. P., Wheeler, C., Deary, J., Weissman, L., Schryber, S., Hunt, M., Critchlow, J., Schnipper, L., Frei, E., III, and Antman, K. H. A Phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J. Clin. Oncol., 9: 320-327, 1991.
25. Coleman, C. N., Halsey, J., Cox, R. S., et al. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR2508 and the pharmacokinetic profile. Cancer Res., 47: 319-322, 1987.
26. Elias, A., Mazanet, R., Wheeler, C., Anderson, K., Ayash, L., Schwartz, G., Tepler, I., Pap, S., Pelaez, J., Gonin, R., Schnipper, L., Griffin, J., Frei, E., and Antman, K. GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection with or without bone marrow as hematological support of high-dose chemotherapy: two protocols. Breast Cancer Treat. Res., 20: S25-S29, 1991.
27. Mehta, C. R., Patel, N. R., and Tsiatis, A. A. Exact significance testing for ordered categorical data. Biometrics, 40: 819-825, 1984.
28. Zar, J. H. Biostatistical Analysis, Ed. 2, pp. 390-395. Englewood Cliffs, NJ: Prentice-Hall, 1984.
29. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
30. Elias, A. D., Eder, J. P., Shea, T., Begg, C. B., Frei, E., III, and Antman, K. H. High-dose ifosfamide with mesna uroprotection: a Phase I study. J. Clin. Oncol., 8: 170-178, 1990.
31. Shea, T. C., Flaherty, M., Elias, A., Eder, J. P., Antman, K., Begg, C., Schnipper, L., Frei, E., III, and Henner, W. D. A Phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J. Clin. Oncol., 7: 651-661, 1989.
32. Brown, J. M. Clinical trials of radiosensitizers: what should we expect? Int. J. Radiat. Oncol. Biol. Phys., 10: 425-429, 1984.
33. Brown, J. M., Yu, N. Y., Brown, D. M., and Lee, W. W. SR-2508: a nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. Int. J. Radiat. Oncol. Biol. Phys., 7: 695-703, 1981.
34. Coleman, C. N., Wasserman, T. H., Urtasun, R. C., Halsey, J., Hirst, V. K., Hancock, S., and Phillips, T. L. Phase I trial of the hypoxic cell radiosensitizer SR-2508. The results of the five to six week drug schedule. Int. J. Radiat. Oncol. Biol. Phys., 12: 1105-1108, 1986.
35. Coleman, C. N., Urtasun, R. C., Wasserman, T. H., Hancock, S., Harris, J. W., Halsey, J., and Hirst, V. K. Initial report of the phase I trial of the hypoxic cell radiosensitizer SR2508. Int. J. Radiat. Oncol. Biol. Phys., 10: 1749-1753, 1984.
36. Coleman, C. N., Noll, L., Riese, N., et al. Final report of the Phase I trial of continuous infusion etanidazole (SR2508): a radiation therapy group study. Int. J. Radiat. Oncol. Biol. Phys., 22: 577-580, 1992.
37. Fields, K. K., Zorsky, P. E., Hiemenz, I. W., Kronish, L. E., and Elfenbein, G. J. Ifosfamide, carboplatin and etoposide: a new regimen with a broad spectrum of activity. J. Clin. Oncol., 12: 544-552, 1994.
38. Wilson, W. H., Jain, V., Bryant, G., Cowan, K. H., Carter, C., Cottler-Fox, M., Goldspiel, B., Steinberg, S. M., Longo, D. L., and Wittes, R. E. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J. Clin. Oncol., 10: 1712-1722, 1992.
39. Bump, E. A., Taylor, Y. C., and Brown, J. M. Role of glutathione in the hypoxic cell cytotoxicity of misonidazole. Cancer Res., 43: 997-1002, 1993.
40. Biaglow, J. E. Cellular electron transfer and radical mechanisms for drug metabolism. Radiat. Res., 86: 212-242, 1981.
41. Mulcahy, R. T., and Trump, D. L. Chemical chemosensitization by misonidazole and related compounds: a critical evaluation. J. Clin. Oncol., 6: 569-573, 1988.
42. Coleman, C. N., Friedman, M. K., Jacobs, C., Halsey, J., Ignoffo, R., Leibel, S., Hirst, V. K., Gribble, M., Carter, S. K., and Phillips, T. L. Phase I trial of i.v. L-phenylalanine mustard plus the sensitizer misonidazole. Cancer Res., 43: 5022-5025, 1983.